Non‐bacterial cystitis with increased expression of programmed death‐ligand 1 in the urothelium: An unusual immune‐related adverse event during treatment with pembrolizumab for lung adenocarcinoma

Non‐bacterial cystitis with increased expression of programmed death‐ligand 1 in the urothelium: An unusual immune‐related adverse event during treatment with pembrolizumab for lung adenocarcinoma

Introduction Immune checkpoint inhibitors are now a standard therapeutic option for lung adenocarcinoma. However, Immune checkpoint inhibitors often induce various immune‐related adverse events. Case presentation The patient was a 78‐year‐old woman with lung adenocarcinoma who had a partial response...

Full description

Bibliographic Details
Main Authors: Yohei Ueki, Masahiro Matsuki, Terufumi Kubo, Rena Morita, Yoshihiko Hirohashi, Syunsuke Sato, Ryota Horibe, Kazuhiko Matsuo, Tomohide Tsukahara, Takayuki Kanaseki, Yasunari Takakuwa, Masaaki Satoh, Naoki Itoh, Toshihiko Torigoe
Format: Article
Language:English
Published: Wiley 2020-11-01
Series:IJU Case Reports
Subjects:
cystitis
immune checkpoint inhibitor
immune‐related adverse event
PD‐L1
Online Access:https://doi.org/10.1002/iju5.12211

Internet

https://doi.org/10.1002/iju5.12211

Similar Items